• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lisata Therapeutics, Inc. - Common Stock (NQ:LSTA)

1.970 -0.090 (-4.37%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Lisata Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
November 06, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’
November 06, 2025
Annual Awards Program Recognizes Breakthrough Life Sciences & Biotechnology Innovation Around the World 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025
October 30, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent
November 04, 2025
Data from Catalent’s preclinical studies evaluating certepetide as a SMARTag® ADC payload showed both improved tumor selective penetration and efficacy 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement
October 08, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial
September 29, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 02, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
August 07, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025
July 31, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update
July 17, 2025
Compelling new preliminary data consistent with previously reported preclinical findings demonstrating certepetide’s potential ability to enhance the effectiveness of immunotherapy 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide
July 15, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata’s Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer
June 26, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development
June 17, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics to Present at the 2025 BIO International Convention
June 11, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 08, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025
May 01, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Announces Research License with Catalent
April 15, 2025
Catalent to evaluate certepetide with its SMARTag® antibody-drug conjugate platform 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics to Present at the Investival Showcase USA
March 06, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development
March 05, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
February 27, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025
February 20, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference
February 05, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics and WARPNINE Announce Encouraging Preliminary Results from the Phase 1b/2a iLSTA Trial Evaluating Certepetide in Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma
January 23, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma
January 22, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics to Present at the 2025 Sequire Investor Summit
January 15, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial
December 10, 2024
Phase 1b/2a open-label trial in the U.S. of certepetide in combination with neoadjuvant FOLFIRINOX-based therapies in pancreatic, colon and appendiceal cancers 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics and Kuva Labs Announce Global License Agreement for Solid Tumor Imaging
December 03, 2024
License provides Lisata’s innovative certepetide targeting agent for use with Kuva’s NanoMark™ MR imaging platform to advance non-invasive, high-precision cancer diagnostics 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’
November 19, 2024
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Dave Mazzo, CEO of Lisata Therapeutics Inc. (NASDAQ: LSTA), to Present at NobleCon20
November 12, 2024
Via Investor Brand Network
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap